Bristol-Myers Squibb Company (BMY) 72.64 $BMY Incyte

New Post Public Reply Private Reply Replies (0) Message Board

Jun 26, 2016 at 10:11 AM

Bristol-Myers Squibb Company (BMY) 72.64 $BMY

Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 5:07PM CDT
Incyte (INCY) announced that the FDA has granted Breakthrough Therapy status to Jakafi for the treatment of patients with acute graft-versus-host disease.
INCY: 81.66 (+3.16), LLY: 73.94 (+0.87), BMY: 72.64 (+0.33), NVS: 80.67 (+0.96)

Sickle Cell Partnership Creates Demonstration Project to Treat Children in Angola
BusinessWire - Fri Jun 24, 3:10PM CDT
The Angola Sickle Cell Initiative, a public-private partnership of the Angola Ministry of Health, the Baylor College of Medicine International Pediatric AIDS Initiative (BIPAI), Texas Children's Hospital and Chevron, is teaming up with the global biopharmaceutical company Bristol-Myers Squibb to provide children with sickle cell disease in Angola with an effective medication to which many patients in the country have lacked access.
BMY: 72.64 (+0.33)

Incyte Reports Epacadostat Combination Study Initiation
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 9:59AM CDT
Incyte (INCY) reported that the first patient has been treated in a phase III epacadostat combination study for advanced or metastatic melanoma.
ANIP: 56.27 (+3.48), INCY: 81.66 (+3.16), MRK: 57.68 (+0.64), BMY: 72.64 (+0.33)

Valeritas Appoints David Lewis as Vice President of Marketing
GlobeNewswire - Thu Jun 23, 7:00AM CDT
Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that David Lewis has been named Vice President of Marketing. Mr. Lewis joins the Company with extensive experience successfully building chronic therapeutic brands including several current market-leading brands in diabetes. Notably, Mr. Lewis led the launch of Januvia, one of Merck & Company's first and most successful new product launches in the U.S. diabetes market, and then went on to lead marketing for the global launch of AstraZeneca and Bristol-Myers Squibb's Forxiga for the treatment of type-2 diabetes.
MRK: 57.68 (+0.64), VLRX: (), BMY: 72.64 (+0.33)

SolarCity and Bristol-Myers climb, Adobe and HP stumble
AP - Wed Jun 22, 3:55PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Wednesday:
FDX: 157.89 (+1.38), WGO: 23.15 (+0.20), MUR: 32.41 (+0.84), BMY: 72.64 (+0.33), HPQ: 12.95 (+0.34), ADBE: 96.21 (+2.20)

GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:53AM CDT
GW Pharmaceuticals (GWPH) has selected infantile spasms as the fourth target indication for the development of Epidiolex.
GWPH: 89.14 (+0.57), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), BMY: 72.64 (+0.33)

RedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:11AM CDT
RedHill (RDHL) announced positive results from a phase I study on Yeliva for the treatment of advanced solid tumors.
RDHL: 10.87 (+0.15), ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)

7 Profitable Medical Stocks Ranked as Buys Now
Arpita Dutt - Zacks Investment Research - Tue Jun 21, 2:52PM CDT
It may be tough going for medical stocks but these 7 companies sporting a favorable Zacks Rank are poised to generate profits this year.
ZTS: 47.90 (+0.57), JNJ: 117.38 (+0.92), PFE: 34.59 (+0.12), LGND: 115.11 (+1.28), BMY: 72.64 (+0.33), AMPH: 16.15 (+0.56)

BMS and Biogen to Give Biomanufacturing Keynote Presentations at CHI's Eighth Annual The Bioprocessing Summit
Marketwired - Tue Jun 21, 12:45PM CDT
A Plenary Session at the Bioprocessing Summit in Boston, MA Will Connect Bioprocess Professionals From Across the Industry to Prepare for Next-Generation Biologics
BMY: 72.64 (+0.33)

Gilead Presents Favorable Preliminary Bictegravir HIV Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:21AM CDT
Gilead Sciences (GILD) presented encouraging preliminary data from four pre-clinical and phase I studies evaluating bictegravir for the treatment of HIV.
GILD: 83.37 (+0.92), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), BMY: 72.64 (+0.33)

Vical (VICL) Reports Phase I/II Data on Genital Herpes Vaccine
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 9:12AM CDT
Vical (VICL) presented data from a phase I/II study on its investigational genital herpes vaccine at a meeting of the American Society for Microbiology.
VICL: 4.60 (+0.24), ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)

Glaxo/Innoviva's Closed Triple Combination Tops Phase III
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:30AM CDT
Glaxo (GSK) and Innoviva (INVA) announced positive top-line data from the phase III FULFIL study on the closed triple combination therapy for the treatment of COPD.
INVA: 11.22 (+0.20), TBPH: 23.06 (+0.17), GSK: 42.56 (+0.80), BMY: 72.64 (+0.33)

Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 2:05PM CDT
Epizyme, Inc. (EPZM) reported encouraging preliminary data from its ongoing, global phase II trial on lead pipeline candidate, tazemetostat, at the American Society of Hematology Meeting on Lymphoma Biology.
ABT: 39.63 (+0.89), PFE: 34.59 (+0.12), EPZM: 10.44 (-0.28), BMY: 72.64 (+0.33)

Auris (EARS) Begins Phase III Study for Sudden Deafness
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 9:31AM CDT
Auris Medical (EARS) has started patient enrollment in a second pivotal phase III study (ASSENT) on AM-111 for the treatment of sudden deafness.
EARS: 4.00 (-0.05), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), BMY: 72.64 (+0.33)

Emergent (EBS) BioThrax sBLA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:13AM CDT
Emergent BioSolutions (EBS) announced that the FDA has accepted to review the company's sBLA for manufacturing BioThrax in Building 55.
EBS: 30.65 (-0.68), ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)

Kura (KURA) Begins Dosing in Phase II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 3:18PM CDT
Kura Oncology (KURA) announced the dosing of the first patient in a phase II study on tipifarnib for the treatment of lower risk myelodysplastic syndromes.
JNJ: 117.38 (+0.92), RTRX: 18.49 (+0.01), KURA: 2.69 (+0.04), BMY: 72.64 (+0.33)

Medivation's (MDVN) Pidilizumab Positive in Phase I/II Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:56AM CDT
Medivation (MDVN) announced data from a phase I/II study on pidilizumab for the treatment of pediatric with diffuse intrinsic pontine glioma.
MDVN: 59.26 (+0.37), ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)

Zacks.com featured highlights: B&G Foods, J. M. Smucker, Bristol-Myers Squibb, Pretium Resources and FTI Consulting
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:30AM CDT
Zacks.com featured highlights: B&G Foods, J. M. Smucker, Bristol-Myers Squibb, Pretium Resources and FTI Consulting
BGS: 46.65 (+0.88), BMY: 72.64 (+0.33), FCN: 41.96 (+0.52), PVG: 9.53 (-0.19), SJM: 146.56 (-0.53)

Allergan Glaucoma Gel Stent Filing Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 11:19PM CDT
Allergan plc's (AGN) Premarket Notification Application for the XEN Glaucoma Treatment System has been accepted by the FDA for review.
AGN: 233.51 (+4.96), BMY: 72.64 (+0.33), TLGT: 6.64 (+0.57), AMPH: 16.15 (+0.56)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NIIT Expands with Bluewater: AI-Led Workforce Revolution

Big Moves in Talent Transformation There's a shakeup in the learning space, folks, and it's all about building a more AI-driven future. Today we're dissecting how NIIT Learning Systems Limited, a name that rings a bell in global managed learning, just snapped up Bluewater Learning. Not just a small fry acquisition, oh no—this one's got some meaty implications, tallying...

Ashling's New Feat: Microsoft Recognition in AI

Microsoft's Stamp of Approval for Ashling Ah, recognition—it's not just for egos. When Ashling, an AI consultancy heavyweight, gets a nod from Microsoft, it's worth more than a footnote in the company newsletter. This isn't some participation trophy. Nope, it's a badge saying they know their Data & AI, and Digital & App Innovation inside out. On October 29, 2026,...

United Imaging Surges with 19.43% Revenue Growth in 2026

United Imaging's Remarkable Revenue Surge Coming out of Shanghai, we've got some major numbers to chew on. United Imaging Healthcare (688271.SH)—this isn't your run-of-the-mill medical tech firm—is bringing some serious heat to the market with a 19.43% bump in revenue. We're talking RMB 10.58 billion raked in over just the first nine months of 2026. Those are hefty...

Tata's $450M Bet on India's AI Infrastructure

The Big Bet on AI Infrastructure Here comes Tata Communications, tossing nearly USD 450 million into the pot, betting on a vision that could change India's digital backbone. This isn't just some drop in the bucket; they're talking about laying down 10,000 kilometers of fiber for India's AI super highway. It's a gutsy move, and frankly, it's about time someone shook things...

Hershey's Sweet Results: 2026 Earnings Soar

Hershey's 2026 Q3 Financial Performance: A Closer Look At the end of September, The Hershey Company (NYSE: HSY) dished out some eye-popping numbers for their third quarter. With a net sales increase of 3.0%, they clocked in at $3,275.5 million. More importantly, earnings per share-diluted shot up by a whopping 111.8%, landing at $2.88. Clearly, Hershey’s strategic moves...

FFR Goes Global with Binance Stock Offering

FFR Stock Hits the International Stage Here's something that's sure to rattle a few cages in the world of robotics and international trading. FF EAI Robotics Ecosystem Inc. (NASDAQ:FFR) has just opened up their stock to the global stage via Binance's U.S. stock trading service. For those outside the 'land of the free,' this means eligible investors can now get their hands...

MSM's New Tool Tackles Label Errors with AI Insight

Nailing Label Precision in Real Time The label printing game just got a major new player. MSM Solutions is rolling out its PortalTrack Print Quality Inspection, and it's not just another tool in the shed—this thing's promising to cut down on label errors before they can bite. Imagine turning your good old industrial label printers into sharp-eyed inspectors, thanks to...

LG Energy Sparks Global Innovation with BIC 2026

Innovating Beyond Boundaries with LG Energy The world of battery tech is on fire, and LG Energy Solution is fanning the flames with their Battery Innovation Contest 2026 (BIC 2026). From October 29 to December 6, 2026, universities and research hives across the globe are being beckoned to pour their battery brilliance into this contest. These aren't just any research...

Barco Brings HDR Cinema Home with Kinepolis Kortrijk

A New Chapter in Cinema Projection Ah, Belgium, the land of waffles and apparently, cutting-edge cinema tech. That's right, Barco is bringing their HDR by Barco system to its own backyard in Kortrijk, teaming up with Kinepolis to shake things up. It's not just any expansion—it's a homecoming of sorts. The company's laser cinema magic has already made face time in the...

Digital Science's Game-Changing Jenni AI Acquisition

A Strategic Move in the Research Sector When you're dealing with tech giants and their endless race to corner niche markets, it's the big moves that really catch one's attention. The latest acquisition on the block is Digital Science picking up Jenni AI, a platform trusted by over 8 million students and researchers scattered across 189 countries. Now, that's a hefty user...